Of particular interest are small-molecule inhibitors of specific types of protein kinases that are dysregulated throughout the carcinogenic process and that vary by cancer type, as well as small molecules that permit reactivation of apoptosis, block angiogenesis, or inhibit the misregulation of immune checkpoints [34,45,46]. The gene discussed is WEE1; the disease is cancer.